Hennion & Walsh Asset Management, Inc.
Position in BCRX — Biocryst Pharmaceuticals Inc
CIK 1861642
Parsippany, NJ
Position in BCRX
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$1,084,147
+$206,343 QoQ
Shares Held
113,881
+1.2% QoQ
Ownership
0.045%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in BCRX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Hennion & Walsh Asset Management, Inc. holds $39,326,268 across 12 Drug Manufacturers - Specialty & Generic names. BCRX ranks #7 (2.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TEVA |
Teva Pharmaceutical Industries Ltd
|
337,044 | $10,151,765 | |
| 2 | INDV |
Indivior Pharmaceuticals, Inc.
|
330,691 | $10,079,461 | |
| 3 | SUPN |
Supernus Pharmaceuticals, Inc.
|
88,454 | $4,572,187 | |
| 4 | UTHR |
UNITED THERAPEUTICS Corp
|
6,195 | $3,673,511 | |
| 5 | PCRX |
Pacira BioSciences, Inc.
|
155,396 | $3,511,949 | |
| 6 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
67,341 | $3,242,469 | |
| 7 | BCRX |
Biocryst Pharmaceuticals Inc
This page
|
113,881 | $1,084,147 | |
| 8 | AKBA |
Akebia Therapeutics, Inc.
|
633,253 | $880,221 |
All Filings in BCRX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,084,147 | 113,881 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $877,804 | 112,539 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $650,804 | 85,745 | Shares | Sole | 2025-10-22 | |
| 2025-06-30 | $452,076 | 50,455 | Shares | Sole | 2025-08-07 | |
| No filing history on record for this holder in this stock. | ||||||